Replies to post #79645 on Biotech Values

[DewDiligence]

Intron-A is essentially obsolete, although it still has modest sales in poorer countries, where its lower price relative to Pegasys and Pegintron is an advantage.

This is the 2001 PR announcing ITMN’s license of Infergen from AMGN:
http://sec.gov/Archives/edgar/data/1087432/000091205701520151/a2052097zex-99_1.htm